1 Hawkey CJ.COX-2 inhibitors[J].Lancet, 1999;353:307-14
2 Ehrich EW, Dallob A, Lepeleire ID, Van HA, Riendeau D, Yuan W, et al.Characterization of rofecoxib as a cyclooxygenase-
2 isoform inhibitor and demonstration of analgesia in the dentalmodel[J].Clin Pharmacol Ther, 1999;65:336-47
3 Paulson SK, Hribar JD, Liu NWK, Hajdu E, Bible RH, Jr Piergies A, et al.Metabolism and excretion of (14C)celecoxib in healthy male volunteers[J].Drug Metab Dispos, 2000;28: 308-14
4 Karim A, Tolbert D, Burton E.SC-58635 (celecoxib):a highly selective inhibition of cyclooxygenase-2 disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation[J].Pharm Res, 1997;14:S617-26
5 Scott LJ, Lamb HM.Rofecoxib [J].Drugs, 1999;58:499- 505
6 Chan CC, Boy ce S, Brideau C, Charleson S, Cromlish W, Ethier D, et al.Rofecoxib [Vioxx, MK-0966:4-(4'-methyls ulfonylphenyl)-3-phenyl-2-(5H)-furanone]:a potent and orally active cyclooxygenase-2 inhibitor.Pharmacological and biochemical profiles[J].J Pharmacol Exp Ther, 1999;290:551-
60
7 Day R, Morrison B, Luza A.A randomized trail of efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with OA[J].Arch IntMed, 2000;161:1781-7
8 Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, et al.Effect of specific COX-2 inhibition in osteoarthritis of the knee a 6 week double blind, placebo controlled pilot study of rofecoxib[J].J Rheum, 1999;26:2438-47
9 Fung HB, Kirschenbaum HL.Selective cyclooxygenase-2 inhibitors for the treatment of arthritis[J].Clin Ther, 1999;21:1131-57
10 Mehlisch DR, Mills S.Ex viro assay of COX-2 inhibitation predicts efficacy in post-surgical dental pain with MK-966[J]. Clin Pharmacol Ther, 1998;63:139-45
11 Fricke JBW, Fite S.MK-966 versus naproxen sodium 550 mg in post-surgical dental pain[J].Clin Pharmacol Ther, 1999;65:119-27
12 Reicin AS, Brown J, Jove M.The COX-2 specific inhibitor, rofecoxib, was effective in the treatment of postorthopedic surgical pain[J].Arthritis Rheum, 1999,42:268
13 Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B.Analgesic efficacy of the cyclooxygenase-2 specific inhibitor rofecoxib in post-dental surgery pain:a randomized, controlled trial[J].Clin Ther, 1999, 21:943-53
14 Morrison BW, Daniels SE, Kotey P.Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrheal:a randomized controlled trial[J].Obstet Gynecol, 1999;94:504-8
15 Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ.Comparison of rofecoxib and celecoxib, two cyclooxygenase-
2 inhibitors, in postoperative dental pain:a randomized, placebo and active-comparator-controlled clinical trial[J].Clin Ther, 1999;21:1653-63
16 Laine L, Harper S, Simon TH.A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis[J].Gastroenterology, 1999;117:776-83
17 Daniels B, Seidenberg B.Cardiovascular safety profile of rofecoxib in controlled clinical trials[J].Arthritis Rheum, 1999; 42:143
18 Daniels B, Gertz B, Morrison B.Renal safety profile of rofecoxib, a specific inhibitor of COX-2 in controlled clinical trials [J].Arthritis Rheum, 1999;42:143
19 Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis [J].N Engl J Med, 2000;343:1520-8
20 Robert J, Campbell, Kevin B.Acute congestive heart failure induced by rofecoxib[J].JABFP, 2004;17:131-5
21 Kumar NP, Wild G, Ramasamy KA, Snape J.Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib[J].Postgrad Med J, 2002;78:439-40
22 Solomon DH, Schneeweiss S, Levin R, Avorn J.Relationship between COX-2 specific inhibitors and hypertension[J].Hypertension, 2004;44:140-5
23 Fitzgerald GA.Coxibs and cardiovascular disease[J].N Engl J Med, 2004;351:1709-10
24 Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F, et al.Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein.A randomised placebo-controlled study[J].Circulation, 2004;110: 934-9
25 Paul EL, Graeme JH, John WE.Cardiovascular safety of rofecoxib (Vioxx):lessons learned and unanswered questions[J]. MJA, 2004;181:524-5
26 http://www.people.com.cn[EB/OL].2004-10-25
27 Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, et al.Celecoxib first report of thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase inhibitors:a report of four cases[J].Arthritis and Rheumatism, 2000;43:1891-6
28 http://www.grrb.com.cn[EB/OL].2004-12-27
29 http://www.worldchinese.net [EB/OL].2004-12-30
30 Neal MD, Fakhreddin J.COX-2 selective inhibitors cardiac toxicity:getting to the heart of the matter[J].J Pharm Pharmaceut Sci, 2004;7:332-6
31 Lucien A.Lessons from the withdrawal of rofecoxib[J].BMJ, 2004;329:1342
32 http://www.incao.com[EB/OL].2004-3 |
